RLRebecca Marie Lynch

Rebecca Marie Lynch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rebecca Marie Lynch has a total of 256 co-authors. Here are the top co-authors by number of shared publications:

  • Kai S. Shimagaki

    Department of Computational and Systems Biology, University of Pittsburgh School of Medicine , Pittsburgh, PA 15213

    5 shared publications
  • John P. Barton

    Department of Computational and Systems Biology, University of Pittsburgh School of Medicine, USA

    4 shared publications
  • Aileen Y. Chang

    Department of Medicine, George Washington University, Washington, DC, USA

    3 shared publications
  • Andrea R. Shiakolas

    Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA

    3 shared publications
  • Andrew Wilson

    Department of Microbiology, Immunology and Tropical Medicine, School of Medicine and Health Sciences, George Washington University, Washington, District of Columbia, USA

    3 shared publications
  • John R. Mascola

    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA

    3 shared publications

Latest Publications

  • Open Access

    Dual role of glycosylation in resistance to CD4-binding site broadly neutralizing antibodies

    by Teresa Murphy, Meagan Kelly, Kai S. Shimagaki, Thomas DeStefanis, Gabriel Galeotos, Myungjin Lee, Qing Wei, Jan Novak, Katharine J. Bar, John P. Barton, et al.

    Broadly neutralizing antibodies (bNAbs) provide a useful tool for HIV cure strategies because of their ability to target conserved regions on the envelope (Env) protein in the context of both virions and infected cells. One of the best-studied bNAbs is the CD4 binding site (CD4bs) antibody VRC01 and others in its class. A major obstacle to effective cure strategies with bNAbs is viral immune escape. A deeper understanding of escape pathways from VRC01-class antibodies in genetically diverse samples is needed. Using an in vitro viral escape assay where infected CD4 + T cells were cultured in the presence of increasing VRC01 concentrations, complete resistance to VRC01 was detected in Env 246.F3 by day 42. We determined that resistance was due to a mutation at position N276 that resulted in elimination of the glycan-attachment site. As the loss of a glycan at this site is known to conversely increase virus sensitivity to CD4bs antibodies, we explored this finding further. Specifically, we introduced the N276D mutation into the 12-virus global Env panel and measured neutralization susceptibility to a panel of CD4bs bNAbs. This N276D mutation increased resistance or sensitivity depending on the Env and bNAb in question, emphasizing a dual role of glycan N276 in VRC01-class bNAb neutralization. The role of this glycan in escape was demonstrated to be dependent on the context of the Env, the bNAb, and the glycosylation complexity of the virus as determined by producer cells. These findings underscore the complexity of glycosylation in antibody escape in genetically diverse HIV. IMPORTANCE: Despite decades of research, an HIV cure remains elusive, largely due to the virus’s immense genetic variability and ability to evade immune clearance. Broadly neutralizing antibodies (bNAbs), particularly those targeting the conserved CD4 binding site such as VRC01 and others in its class, offer promise for cure by targeting both circulating virus and infected cells. However, viral escape from bNAbs remains a critical hurdle. In this study, we demonstrate that glycan-mediated escape from VRC01-class bNAbs is highly context-dependent—shaped by Env, the bNAb, and the glycosylation patterns introduced by the producer cell. These findings emphasize the dual role of glycans in affecting antibody sensitivity (shielding the virus to increase antibody resistance or sometimes providing an epitope that increases antibody sensitivity) and underscore the importance of viral and host factors in shaping effective bNAb-based cure strategies across diverse HIV-1 strains.


  • Open Access

    Predicting viral sensitivity to antibodies using genetic sequences and antibody similarities

    by Kai S. Shimagaki, Gargi Kher, Rebecca M. Lynch, John P. Barton

    For genetically variable pathogens such as human immunodeficiency virus (HIV)-1, individual viral isolates can differ dramatically in their sensitivity to antibodies. The ability to predict which viruses will be sensitive and which will be resistant to a specific antibody could aid in the design of antibody therapies and help illuminate resistance evolution. Due to the enormous number of possible combinations, it is not possible to experimentally measure neutralization values for all pairs of viruses and antibodies. Here, we developed a simple and interpretable method called grouped neutralization learning (GNL) to predict neutralization values by leveraging viral genetic sequences and similarities in neutralization profiles between antibodies. The trained model is interpretable and can identify key mutations that impact viral sensitivity. Our method compares favorably to state-of-the-art approaches and is robust to model parameter assumptions. GNL can predict neutralization values for viral sequences without observed neutralization measurements, an important capability for assessing antibody coverage in populations whose viral diversity is genetically characterized. We also demonstrate that GNL can successfully transfer knowledge between independent data sets, allowing rapid estimates of viral sensitivity based on prior knowledge.

  • Open Access

    Parallel HIV-1 fitness landscapes shape viral dynamics in humans and macaques that develop broadly neutralizing antibodies

    by Kai S Shimagaki, Rebecca M Lynch, John P Barton

    HIV-1 evolves within individual hosts to escape adaptive immune responses while maintaining its capacity for replication. Coevolution between HIV-1 and the immune system generates extraordinary viral genetic diversity. In some individuals, this process also results in the development of broadly neutralizing antibodies (bnAbs) that can neutralize many viral variants, a key focus of HIV-1 vaccine design. However, a general understanding of the forces that shape virus-immune coevolution within and across hosts remains incomplete. Here, we performed a quantitative study of HIV-1 evolution in humans and rhesus macaques, including individuals who developed bnAbs. We observed strong selection early in infection for mutations affecting HIV-1 envelope glycosylation and escape from autologous strain-specific antibodies, followed by weaker selection for bnAb resistance. The inferred fitness effects of HIV-1 mutations in humans and macaques were remarkably similar. Moreover, we observed a striking pattern of rapid HIV-1 fitness gains that precedes the development of bnAbs. Our work highlights strong parallels between infection in rhesus macaques and humans, and it reveals a quantitative evolutionary signature of bnAb development.


  • Open Access

    Predicting viral sensitivity to antibodies using genetic sequences and antibody similarities

    by Kai S. Shimagaki, Gargi Kher, Rebecca M. Lynch, John P. Barton

    For genetically variable pathogens such as human immunodeficiency virus (HIV)-1, individual viral isolates can differ dramatically in their sensitivity to antibodies. The ability to predict which viruses will be sensitive and which will be resistant to a specific antibody could aid in the design of antibody therapies and help illuminate resistance evolution. Due to the enormous number of possible combinations, it is not possible to experimentally measure neutralization values for all pairs of viruses and antibodies. Here, we developed a simple and interpretable method called grouped neutralization learning (GNL) to predict neutralization values by leveraging viral genetic sequences and similarities in neutralization profiles between antibodies. Our method compares favorably to state-of-the-art approaches and is robust to model parameter assumptions. GNL can predict neutralization values for viruses with no observed data, an essential capability for evaluating novel viral strains. We also demonstrate that GNL can successfully transfer knowledge between independent data sets, allowing rapid estimates of viral sensitivity based on prior knowledge.

  • Open Access

    Dual Role of Glycosylation in Resistance to CD4-binding Site Broadly Neutralizing Antibodies

    by Teresa Murphy, Meagan Kelly, Kai S. Shimagaki, Thomas DeStefanis, Gabriel Galeotos, Myungjin Lee, Qing Wei, Jan Novak, Katharine J. Bar, John P. Barton, et al.

    Broadly neutralizing antibodies (bNAbs) provide a useful tool for HIV cure strategies because of their ability to target conserved regions on the envelope (Env) protein in the context of both virions and infected cells. One of the most well studied bNAbs is the CD4 binding site (CD4bs) antibody, VRC01 and others in its class. A major obstacle to effective cure strategies with bNAbs is viral immune escape. A deeper understanding of escape pathways from VRC01-class antibodies in genetically diverse samples is needed. Using an in vitro viral escape assay where infected CD4 + T cells were cultured in the presence of increasing VRC01 concentrations, complete resistance to VRC01 was detected in Env 246.F3 by day 42. We determined that resistance was due to a mutation at position N276 that resulted in elimination of the glycan-attachment site. As the loss of a glycan at this site is known to increase virus sensitivity to CD4bs antibodies, we explored this finding further. Specifically, we introduced N276D mutation into the 12-virus global Env panel and measured neutralization susceptibility to a panel of CD4bs bNAbs. This N276D mutation increased resistance or sensitivity depending on the Env and bNAb in question, emphasizing a dual role of glycan N276 in VRC01-class bNAb neutralization. The role of this glycan in escape was demonstrated to be dependent on the context of the Env, the bNAb and the glycosylation complexity of the virus due to producer cells. These findings underscore the complexity of glycosylation in genetically diverse HIV escape from antibodies. Importance: Despite decades of research, an HIV cure remains elusive, largely due to the virus’s immense genetic variability and ability to evade immune clearance. While antiretroviral therapy (ART) suppresses viral replication, it does not eradicate the virus and presents long-term challenges related to toxicity, access, and adherence. Broadly neutralizing antibodies (bNAbs), particularly those targeting the conserved CD4 binding site such as VRC01 and others in its class, offer promise for durable control or cure by targeting both circulating virus and infected cells. However, viral escape from bNAbs remains a critical hurdle. In this study, we demonstrate that glycan-mediated escape from VRC01-class bNAbs is highly context-dependent—shaped by Env, bNAb, and the glycosylation patterns introduced by the producer cell. These findings emphasize the dual role of glycans in affecting antibody sensitivity and underscore the importance of viral and host factors in shaping effective bNAb-based cure strategies across diverse HIV-1 strains.

  • Open Access

    Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection

    by Myra Happe, Rebecca M. Lynch, Carl J. Fichtenbaum, Sonya L. Heath, Susan L. Koletar, Raphael J. Landovitz, Rachel M. Presti, Jorge L. Santana-Bagur, Randall L. Tressler, LaSonji A. Holman, et al.

    BACKGROUND: HIV-1–specific broadly neutralizing monoclonal antibodies (bNAbs) have emerged as promising interventions with the potential to effectively treat and prevent HIV-1 infections. We conducted a phase I clinical trial evaluating the potent CD4-binding site–specific (CD4bs-specific) bNAbs VRC01LS and VRC07-523LS in people with HIV-1 (PWH) not receiving antiretroviral therapy (ART). METHODS: Participants received a single intravenous 40 mg/kg dose of either VRC01LS ( n = 7) or VRC07-523LS ( n = 9) and did not initiate ART for a minimum of 14 days. The primary study objective was to evaluate safety and tolerability; the secondary study objectives were to evaluate pharmacokinetics (PK) and the impact of administered bNAbs on viral loads (VL) and CD4 + T cell counts in the absence of ART. RESULTS: This trial enrolled 16 PWH aged 20 to 57 years. Both bNAbs were safe and well tolerated. Mild local reactogenicity was only reported in participants who received VRC07-523LS, while both bNAbs were associated with mild systemic symptoms. Maximum serum concentrations (C max ) following VRC01LS or VRC07-523LS were 1,566 ± 316 and 1,295 ± 376 μg/mL, respectively. VRC07-523LS administration significantly decreased VL in 8 out of 9 participants, with an average decline of 1.7 ± 0.8 log 10 copies/mL within 14 days after administration. In contrast, VRC01LS administration resulted in a smaller average decline (0.8 ± 0.8 log 10 copies/mL), and 3 out of 7 participants showedno change in VL. Postinfusion maximum decline in VL correlated with post hoc baseline in vitro viral susceptibility results for both bNAbs. CONCLUSION: The results of this trial support inclusion of potent CD4bs-specific bNAbs, such as VRC07-523LS, into next-generation treatment regimens for HIV-1. TRIAL REGISTRATION: ClinicalTrials.gov NCT02840474. FUNDING: National Institute of Allergy and Infectious Diseases (NIAID)/NIH (grants UM1 AI068634, UM1 AI068636, UM1 AI106701, UM1AI069424, UM1AI069501, UM1AI69415, UM1AI069534, UM1AI69494); the Intramural Research Program of the NIAID/NIH; National Center for Advancing Translational Sciences/NIH (grants UM1TR004548, UL1TR001881, and UL1TR001878); and the National Cancer Institute/NIH (contract 75N91019D00024).


  • Open Access

    Analysis of Memory Antibody Responses in Individuals with Zika-Associated Guillain–Barré Syndrome

    by Michelle Premazzi Papa, Grace Mantus, Kareem Kabra, Carlos Herrera Gomez, Adam Ward, Liliana Encinales, Andres Cadena, Aileen Chang, Rebecca M. Lynch

    The Zika virus (ZIKV) was responsible for a major outbreak in 2015 in the Americas. Infections were associated with increased cases of microcephaly in infants and Guillain–Barré Syndrome (GBS) in adults. Our group previously demonstrated that Zika-associated GBS correlated with the increased neutralization of ZIKV and DENV2, but the antibody specificity was not analyzed. Here, we generated reporter virus particles (RVPs) of ZIKV with specific-point mutations that allowed us to investigate the specificity of circulating plasma antibodies at two different timepoints from individuals with Zika-associated GBS. We found that neutralizing antibody titers to ZIKV waned between one and two years post-ZIKV infection in GBS-negative but not GBS-positive individuals. Interestingly, plasma neutralization by GBS-negative individuals was more sensitive to a mutation at position N154A than plasma from GBS-positive individuals. To determine if waning was associated with different levels of B-cell activation at the time of infection, pro-inflammatory cytokines were measured, but no differences were observed in people with or without GBS. These data suggest subtle differences between GBS-positive and-negative individuals’ circulating antibodies, where antibodies from GBS-positive individuals may target different epitopes and remain in circulation longer as compared to GBS-negative individuals.


  • Open Access

    Dengue NS1 Antibodies Are Associated With Clearance of Viral Nonstructural Protein-1

    by Michelle Premazzi Papa, Evelyn Mendoza-Torres, Peifang Sun, Liliana Encinales, Joseph Goulet, Gabriel Defang, Jani Vihasi, Ying Cheng, Karol Suchowiecki, Wendy Rosales, et al.

    Background: Dengue vascular permeability syndrome is the primary cause of death in severe dengue infections. The protective versus potentially pathogenic role of dengue nonstructural protein-1 (NS1) antibodies are not well understood. The main goal of this analysis was to characterize the relationship between free NS1 concentration and NS1 antibody titers in primary and secondary dengue infection to better understand the presence and duration of NS1 antibody complexes in clinical dengue infections. Methods: Hospitalized participants with acute dengue infection were recruited from Northern Colombia between 2018 and 2020. Symptom assessment, including dengue signs and symptoms, chart review, and blood collection, was performed. Primary versus secondary dengue was assessed serologically. NS1 titers and anti-NS1 antibodies were measured daily. Results: Patients with secondary infection had higher antibody titers than those in primary infection, and there was a negative correlation between anti-NS1 antibody titer and NS1 protein. We demonstrate that in a subset of secondary infection, there were indeed NS1 antigen-antibody complexes on the admission day during the febrile phase that were not detectable by the recovery phase. Furthermore, dengue infection status was associated with higher circulating sialidases. Discussion: The negative correlation between antibody and protein suggests that antibodies may play a role in clearing this viral protein.


  • Open Access

    Autologous neutralizing antibody responses after antiretroviral therapy in acute and early HIV-1

    by Gregory D. Whitehill, Jaimy Joy, Francesco E. Marino, Ryan J. Krause, Suvadip Mallick, Hunter M. Courtney, Kyewon Park, John W. Carey, Rebecca Hoh, Heather Hartig, et al.

    BACKGROUND: Early antiretroviral therapy initiation (ARTi) in HIV-1 restricts reservoir size and diversity while preserving immune function, potentially improving opportunities for immunotherapeutic cure strategies. For antibody-based cure approaches, the development of autologous neutralizing antibodies (anAbs) after acute/early ARTi is relevant but is poorly understood. METHODS: We characterized antibody responses in a cohort of 23 participants following ARTi in acute HIV (<60 days after acquisition) and early HIV (60–128 days after acquisition). RESULTS: Plasma virus sequences at the time of ARTi revealed evidence of escape from anAbs after early, but not acute, ARTi. HIV-1 envelopes representing the transmitted/founder virus(es) (acute ARTi) or escape variants (early ARTi) were tested for sensitivity to longitudinal plasma IgG. After acute ARTi, no anAb responses developed over months to years of suppressive ART. In 2 of the 3 acute ARTi participants who experienced viremia after ARTi, however, anAbs arose shortly thereafter. After early ARTi, anAbs targeting those early variants developed between 12 and 42 weeks of ART and continued to increase in breadth and potency thereafter. CONCLUSION: Results indicate a threshold of virus replication (~60 days) required to induce anAbs, after which they continue to expand on suppressive ART to better target the range of reservoir variants. TRIAL REGISTRATION: ClinicalTrials.gov NCT02656511. FUNDING: NIH grants U01AI169767, R01AI162646, UM1AI164570, UM1AI164560, U19AI096109, K23GM112526, T32AI118684, P30AI045008, P30AI027763, R24AI067039; Gilead Sciences grant INUS2361354; Viiv Healthcare grant A126326.